CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy
Alfarsi, Lutfi; Ansari, Rokaya El; Craze, Madeleine L.; Toss, Michael S.; Masisi, Brendah; Ellis, Ian O.; Rakha, Emad A.; Green, Andrew R.
Rokaya El Ansari
Madeleine L. Craze
MICHAEL TOSS Michael.Toss@nottingham.ac.uk
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
Emad A. Rakha
Andrew R. Green email@example.com
Endocrine therapy is the standard treatment for oestrogen receptor positive (ER+) breast cancer. Despite its efficacy, around half of patients will develop resistance to this treatment and eventually relapse. Identification of effective and reliable biomarkers to predict the efficacy of endocrine therapy is of crucial importance in the management of ER+ breast cancer. Emerging evidence has revealed that the cell division regulator CDC20 exhibits an oncogenic function and plays important roles in tumourigenesis and progression of solid tumours. In this study, we investigated the prognostic and predictive role of CDC20 in early ER+ breast cancer patients.
The biological and clinical impact of CDC20 expression was assessed in large clinical annotated cohort of ER+ breast cancer with long-term follow-up at the mRNA level, using METABRIC and KM-Plotter datasets, and the protein level using immunohistochemistry on patients presenting at Nottingham. CDC20 expression was correlated with clinico-pathological parameters, molecular subtypes, clinical outcome and efficacy of endocrine therapy.
High CDC20 mRNA expression was associated with poor clinico-pathological parameters including large tumour size and high tumour grade (P
|Journal Article Type||Article|
|Journal||Breast Cancer Research and Treatment|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Alfarsi, L., Ansari, R. E., Craze, M. L., Toss, M. S., Masisi, B., Ellis, I. O., …Green, A. R. (2019). CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 178(3), 535-544. https://doi.org/10.1007/s10549-019-05420-8|
|Keywords||CDC20; breast cancer; ER; endocrine resistance; predictive biomarker|
This file is under embargo until Aug 31, 2020 due to copyright restrictions.
You might also like
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
A novel prognostic two-gene signature for triple negative breast cancer
The prognostic significance of ALDH1A1 expression in early invasive breast cancer